Long-term plateletpheresis in the management of primary thrombocytosis. 1979

D Goldfinger, and R Thompson, and C Lowe, and L Kurz, and G Belkin

We attempted to control the platelet count of a patient with primary thrombocytosis utilizing long-term plateletpheresis therapy. The patient previously could not be controlled with chemotherapy, because of rapid development of leukopenia. Although intensive pheresis at the rate of four to five procedures per week produced rapid lowering of the patient's platelet count, continued therapy at the rate of two to three procedures a week failed to maintain these counts, and platelets gradually rose to pretreatment levels. We conclude that while plateletpheresis can produce acute lowering of elevated platelet counts, the rate of platelet production in primary thrombocytosis may be too rapid to allow for long-term control by pheresis alone, utilizing an acceptable treatment schedule of one of three procedures per week.

UI MeSH Term Description Entries
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010983 Plateletpheresis The preparation of platelet concentrates with the return of red cells and platelet-poor plasma to the donor. Blood Plateletpheresis,Thrombocytapheresis,Thrombocytopheresis,Blood Plateletphereses,Plateletphereses,Plateletphereses, Blood,Plateletpheresis, Blood,Thrombocytaphereses,Thrombocytophereses
D001803 Blood Transfusion The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed) Blood Transfusions,Transfusion, Blood,Transfusions, Blood
D002066 Busulfan An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. Busulphan,Busulfan Wellcome,Busulfex,Glyzophrol,Myelosan,Mylecytan,Myleran,Myléran,n-Butane-1,3-di(methylsulfonate),Wellcome, Busulfan
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013922 Thrombocytosis Increased numbers of platelets in the peripheral blood. (Dorland, 27th ed) Thrombocythemia,Thrombocythemias,Thrombocytoses

Related Publications

D Goldfinger, and R Thompson, and C Lowe, and L Kurz, and G Belkin
November 1977, Blood,
D Goldfinger, and R Thompson, and C Lowe, and L Kurz, and G Belkin
October 1982, [Rinsho ketsueki] The Japanese journal of clinical hematology,
D Goldfinger, and R Thompson, and C Lowe, and L Kurz, and G Belkin
January 2009, Annals of hematology,
D Goldfinger, and R Thompson, and C Lowe, and L Kurz, and G Belkin
January 1980, Transfusion,
D Goldfinger, and R Thompson, and C Lowe, and L Kurz, and G Belkin
June 2018, World neurosurgery,
D Goldfinger, and R Thompson, and C Lowe, and L Kurz, and G Belkin
February 1980, The New Zealand medical journal,
D Goldfinger, and R Thompson, and C Lowe, and L Kurz, and G Belkin
April 1980, Die Medizinische Welt,
D Goldfinger, and R Thompson, and C Lowe, and L Kurz, and G Belkin
December 2004, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy,
D Goldfinger, and R Thompson, and C Lowe, and L Kurz, and G Belkin
August 1993, Cancer,
D Goldfinger, and R Thompson, and C Lowe, and L Kurz, and G Belkin
October 1982, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Copied contents to your clipboard!